Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor-Reference-Cited by-同舟云学术

Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor

Published:2018-07 Issue:1 Volume:200 Page:126-135
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Leão Ricardo¹²,van Agthoven Ton³,Figueiredo Arnaldo²,Jewett Michael A.S.¹,Fadaak Kamel¹,Sweet Joan⁴,Ahmad Ardalan E.¹,Anson-Cartwright Lynn¹,Chung Peter⁵,Hansen Aaron⁶⁷,Warde Padraig⁵,Castelo-Branco Pedro⁸,O’Malley Martin⁹,Bedard Philippe L.⁷,Looijenga Leendert H.J.³,Hamilton Robert J.¹

Affiliation:

1. Department of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

2. Faculty of Medicine, University of Coimbra, Coimbra, Portugal

3. Department of Pathology, Laboratory for Experimental Patho-Oncology, Erasmus MC Cancer Institute, Erasmus MC University Medical Center, Rotterdam, The Netherlands

4. Department of Pathology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

5. Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

6. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

7. Department of Medicine, University of Toronto, Toronto, Ontario, Canada

8. Centre for Biomedical Research (CBMR), University of Algarve, Faro, Portugal

9. Department of Medical Imaging, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference30 articles.

1. NORDCAN—a Nordic tool for cancer information, planning, quality control and research;Engholm;Acta Oncol,2010

2. EAU guidelines on testicular cancer: 2011 update. European Association of Urology;Albers;Actas Urol Esp,2012

3. Serum tumor markers in the evaluation of male germ cell tumors;Barlow;Nat Rev Urol,2010

4. Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle;Gillis;Mol Oncol,2013

5. Retroperitoneal metastases in testicular cancer: role of CT measurements of residual masses in decision making for resection after chemotherapy;Steyerberg;Radiology,2000

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. miR-21, miR-29a, and miR-106b: serum and tissue biomarkers with diagnostic potential in metastatic testicular cancer;Scientific Reports;2024-08-30

2. Biomarkers of prostate bladder and testicular cancers: current use in anatomic pathology and future directions;Surgical and Experimental Pathology;2024-08-20

3. Hodentumor – welche Vorteile bringt der neue Tumormarker microRNA-371a-3p (M371-Test);Aktuelle Urologie;2024-08-12

4. MicroRNA for Prediction of Teratoma and Viable Germ Cell Tumor after Chemotherapy;Urologic Clinics of North America;2024-08

5. Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours;European Urology Focus;2024-05